Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.73 |
| ▸ | TP53 | P04637 | 6/20 | 0.73 |
| ▸ | MAPT | P10636 | 8/20 | 0.66 |
| ▸ | NPC1 | O15118 | 7/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.63 |
| ▸ | RAB9A | P51151 | 6/20 | 0.63 |
| ▸ | MITF | O75030 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3225794 | 0.94 | SMN1; SMN2 (0.72) | SMN1; SMN2TP53MAPTNPC1KDM4E | |
| SCHEMBL3226069 | 0.91 | SMN1; SMN2 (0.76) | SMN1; SMN2TP53MAPTNPC1KDM4E | |
| SCHEMBL3229129 | 0.85 | SMN1; SMN2 (0.78) | SMN1; SMN2TP53MAPTNPC1KDM4E | |
| SCHEMBL3213720 | 0.84 | SMN1; SMN2 (0.67) | SMN1; SMN2TP53MAPTNPC1KDM4E | |
| SCHEMBL3224286 | 0.83 | MAPT (0.73) | SMN1; SMN2TP53MAPTNPC1KDM4E | |
| SCHEMBL3226187 | 0.82 | MAPT (0.68) | SMN1; SMN2TP53MAPTNPC1KDM4E | |
| SCHEMBL3226073 | 0.79 | MAPT (0.67) | SMN1; SMN2TP53MAPTNPC1KDM4E | |
| SCHEMBL3229062 | 0.79 | SMN1; SMN2 (0.77) | SMN1; SMN2TP53MAPTNPC1KDM4E | |
| SCHEMBL3223174 | 0.79 | NPC1 (0.76) | SMN1; SMN2TP53MAPTNPC1KDM4E | |
| SCHEMBL27759196 | 0.79 | MAPT (0.64) | SMN1; SMN2TP53MAPTNPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | BIOMARIN IGA LIMITED | 2010-07-01 | — | — | US | claimed |
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | BIOMARIN IGA LIMITED | 2010-07-01 | — | — | US | disclosed |
| US-20100048660-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED (BS) | 2010-02-25 | — | — | US | disclosed |
| CN-101420952-A | Treatment of duchenne muscular dystrophy | SUMMIT CORP PLC (GB) | 2009-04-29 | — | — | CN | disclosed |
| EP-1986643-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091107-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048660-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SMN1; SMN2, CPT1B, GYS1 | SMN1; SMN2 1/4885TP53 4078/4885MAPT 4772/4885 |
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | CPT1B, PYGM, MTPN | SMN1; SMN2 5/4885TP53 4863/4885MAPT 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.